Neuro-Oncology Reviews
Volume
26 Number 24
31 October 2024
Home > Publications > Neuro-Oncology Reviews > Volume 26, Year 2024 > Number 24, 31 October
Manan HA, Aidilla Sahrizan NS, Palaniandy K, Hamid HA, Yahya N.
The utilisation of fMRI for
pre-operative mapping in the paediatric population with central
nervous system tumours: a systematic review.
Neuroradiology.
2024 Oct 21. doi:
10.1007/s00234-024-03489-7. PMID:
39432073. Review˰ ˍ
Noor L, Upadhyay A, Joshi V.
Role of T
Lymphocytes in Glioma Immune Microenvironment: Two Sides of a
Coin.
Biology
(Basel). 2024 Oct 21;13(10):846. doi:
10.3390/biology13100846. PMID:
39452154. Review. ˍ
Ghadami E, Jafari M, Razipour M, Maghsudlu M, Ghadami M.
Circular
RNAs in glioblastoma.
Clin
Chim Acta. 2024 Oct 22;565:120003. doi:
10.1016/j.cca.2024.120003. PMID:
39447824. Review˰ ˍ
Wang N, Yuan Y, Hu T, Xu H, Piao H.
Metabolism:
an important player in glioma survival and development.
Discov
Oncol. 2024 Oct 22;15(1):577. doi:
10.1007/s12672-024-01402-5. PMID:
39436434. Review. ˍ
Yang X, Gao X, Jiang X, Yue K, Luo P.
Targeting
capabilities of engineered extracellular vesicles for the
treatment of neurological diseases.
Neural
Regen Res. 2024 Oct 22. doi:
10.4103/NRR.NRR-D-24-00462. PMID:
39435635. Review. ˍ
Zhang X, Tan Y, He X, Huang J, Ni X, Hu Q, Cai J.
The
diagnostic accuracy of exosomes for glioma: A meta-analysis.
Biomol
Biomed. 2024 Oct 22. doi:
10.17305/bb.2024.11268. PMID:
39465690. Meta-analysis. ˍ
Baumert BG, P M Jaspers J, Keil VC, Galldiks N, Izycka-Swieszewska
E, Timmermann B, Grosu AL, Minniti G, Ricardi U, Dhermain F, Weber
DC, van den Bent M, Rudà R, Niyazi M, Erridge S.
ESTRO-EANO guideline on target
delineation and radiotherapy for IDHmutant WHO CNS grade 2 and 3
diffuse glioma.
Radiother
Oncol. 2024 Oct 23:110594. doi:
10.1016/j.radonc.2024.110594. PMID:
39454886. Guidelines. ˍ
Broggi G, Mazzucchelli M, Salzano S, Barbagallo GMV, Certo F,
Zanelli M, Palicelli A, Zizzo M, Koufopoulos N, Magro G,
Caltabiano R.
The emerging role of
artificial intelligence in neuropathology: Where are we and where
do we want to go?
Pathol
Res Pract. 2024 Oct 23;263:155671. doi:
10.1016/j.prp.2024.155671. PMID:
39490225. Review. ˍ
Dhanavath N, Bisht P, Jamadade MS, Murti K, Wal P, Kumar N.
Olaparib: A Chemosensitizer for the
Treatment of Glioblastoma.
Mini
Rev Med Chem. 2024 Oct 23. doi:
10.2174/0113895575318854241014101928. PMID:
39444180. Review˰ ˍ
Huang R, Lu X, Sun X, Wu H.
Metabolomic
profiling of childhood medulloblastoma: contributions and
relevance to diagnosis and molecular subtyping.
J
Cancer Res Clin Oncol. 2024 Oct 23;150(10):471. doi:
10.1007/s00432-024-05990-1. PMID:
39441459. Review. ˍ
Kurdi M, Bamaga A, Alkhotani A, Alsharif T, Abdel-Hamid GA, Selim
ME, Alsinani T, Albeshri A, Badahdah A, Basheikh M, Baeesa
S.
Mitochondrial DNA Alterations in
Glioblastoma and Current Therapeutic Targets.
Front
Biosci (Landmark Ed). 2024 Oct 23;29(10):367. doi:
10.31083/j.fbl2910367. PMID:
39473421. Review. ˍ
Lim-Fat MJ, Bennett J, Ostrom Q, Touat M, Franceschi E, Schulte J,
Bindra RS, Fangusaro J, Dhall G, Nicholson J, Jackson S, Davidson
TB, Calaminus G, Robinson G, Whittle JR, Hau P, Ramaswamy V,
Pajtler KW, Rudà R, Foreman NK, Hervey-Jumper SL, Das S,
Dirks P, Bi WL, Huang A, Merchant TE, Fouladi M, Aldape K, Van den
Bent MJ, Packer RJ, Miller JJ, Reardon DA, Chang SM, Haas-Kogan D,
Tabori U, Hawkins C, Monje M, Wen PY, Bouffet E, Yeo KK.
Central
nervous system tumors in adolescents and young adults: A Society
for Neuro-Oncology consensus review on diagnosis, management, and
future directions.
Neuro
Oncol. 2024 Oct 23:noae186. doi:
10.1093/neuonc/noae186. PMID:
39441704. Review; Guidelines. ˍ
Sarantopoulos A, Ene C, Aquilanti E.
Therapeutic
approaches to modulate the immune microenvironment in gliomas.
NPJ
Precis Oncol. 2024 Oct 23;8(1):241. doi:
10.1038/s41698-024-00717-4. PMID:
39443641. Review. ˍ
Zhang L, Wang Y, Cai X, Mao X, Sun H.
Deciphering
the CNS-glioma dialogue: Advanced insights into CNS-glioma
communication pathways and their therapeutic potential.
J
Cent Nerv Syst Dis. 2024 Oct 23;16:11795735241292188.
doi:
10.1177/11795735241292188. PMID:
39493257. Review. ˍ
Gallus M, Young JS, Cook Quackenbush S, Khasraw M, de Groot J,
Okada H.
Chimeric antigen receptor
T-cell therapy in patients with malignant glioma-From
neuroimmunology to clinical trial design considerations.
Neuro
Oncol. 2024 Oct 24:noae203. doi:
10.1093/neuonc/noae203. PMID:
39450490. Review. ˍ
Geraldo AF, Maldonado F, Severino M, Mankad K, Dahmoush H, Soares
B, Rugilo C, Rossi A.
Response
assessment in pediatric neurooncology (RAPNO) criteria revisited:
a practical navigation guide for
neuroradiologists.
Neuroradiology.
2024 Oct 24. doi:
10.1007/s00234-024-03493-x. PMID:
39446196. Guidelines˰ ˍ
Liu J, Wang P, Zhang H, Guo Y, Tang M, Wang J, Wu N.
Current
research status of Raman spectroscopy in glioma detection.
Photodiagnosis
Photodyn Ther. 2024 Oct 24:104388. doi:
10.1016/j.pdpdt.2024.104388. PMID:
39461488. Review. ˍ
Tang Q, Ren T, Bai P, Wang X, Zhao L, Zhong R, Sun G.
Novel
strategies to overcome chemoresistance in human glioblastoma.
Biochem
Pharmacol. 2024 Oct 24;230(Pt 2):116588. doi:
10.1016/j.bcp.2024.116588. PMID:
39461382. Review. ˍ
Wang C, Duan L, Zhao Y, Wang Y, Li Y.
Efficacy
and safety of bevacizumab combined with temozolomide in the
treatment of glioma a systematic review and meta-analysis of
clinical trials.
World Neurosurg. 2024 Oct
24:S1878-8750(24)01775-3? doi:
10.1016/j.wneu.2024.10.071? PMID:
39461419. Review; Meta-analysis˰
ˍ
Cacciotti C, Tabori U, Hawkins C, Bennett J.
Targeting
the RAS/MAPK pathway in children with glioma.
J
Neurooncol. 2024 Oct 25. doi:
10.1007/s11060-024-04857-2. PMID:
39448518. Review˰ ˍ
Xiong J, Zhou X, Su L, Jiang L, Ming Z, Pang C, Fuller C, Xu K,
Chi H, Zheng X.
The two-sided
battlefield of tumour-associated macrophages in glioblastoma:
unravelling their therapeutic potential.
Discov
Oncol. 2024 Oct 25;15(1):590. doi:
10.1007/s12672-024-01464-5. PMID:
39453528. Review. ˍ
Ehret F, Baya LE, Erridge SC, Bussière M, Verhoeff J,
Niyazi M, Preusser M, Minniti G, Shih HA.
Radiotherapy
for Meningiomas - Where Do We Stand and What's on the Horizon?
Int J Radiat Oncol Biol Phys. 2024 Oct
28:S0360-3016(24)03525-9. doi:
10.1016/j.ijrobp.2024.10.034. PMID:
39476990. Review. ˍ
Huang L, Zhan J, Li Y, Huang K, Zhu X, Li J.
The
roles of extracellular vesicles in gliomas: Challenge or
opportunity?
Life
Sci. 2024 Oct 28;358:123150. doi:
10.1016/j.lfs.2024.123150. PMID:
39471898. Review˰ ˍ
Mohamed AH, Obeid RA, Fadhil AA, Amir AA, Adhab ZH, Jabouri EA,
Ahmad I, Alshahrani MY.
BTLA and HVEM:
Emerging players in the tumor microenvironment and cancer
progression.
Cytokine.
2023 Oct 28;172:156412. doi:
10.1016/j.cyto.2023.156412. PMID:
39492110. Review˰ ˍ
Norollahi SE, Yousefi B, Nejatifar F, Yousefzadeh-Chabok S,
Rashidy-Pour A, Samadani AA.
Practical
immunomodulatory landscape of glioblastoma multiforme (GBM)
therapy.
J
Egypt Natl Canc Inst. 2024 Oct 28;36(1):33. doi:
10.1186/s43046-024-00240-4. PMID:
39465481. Review. ˍ
Suh HN, Choi GE.
Wnt signaling in the
tumor microenvironment: A driver of brain tumor dynamics.
Life
Sci. 2024 Oct 28;358:123174. doi:
10.1016/j.lfs.2024.123174. PMID:
39471897. Review. ˍ
Villanueva-Meyer JE, Bakas S, Tiwari P, Lupo JM, Calabrese E,
Davatzikos C, Bi WL, Ismail M, Akbari H, Lohmann P, Booth TC,
Wiestler B, Aerts HJWL, Rasool G, Tonn JC, Nowosielski M, Jain R,
Colen RR, Pati S, Baid U, Vollmuth P, Macdonald D, Vogelbaum MA,
Chang SM, Huang RY, Galldiks N; Response Assessment in Neuro
Oncology (RANO) group.
Artificial
Intelligence for Response Assessment in Neuro Oncology (AI-RANO),
part 1: review of current advancements.
Lancet
Oncol. 2024 Oct 28;25(11):e581-e588. doi:
10.1016/S1470-2045(24)00316-4. PMID:
39481414. Review˰ ˍ
Bakas S, Vollmuth P, Galldiks N, Booth TC, Aerts HJWL, Bi WL,
Wiestler B, Tiwari P, Pati S, Baid U, Calabrese E, Lohmann P,
Nowosielski M, Jain R, Colen R, Ismail M, Rasool G, Lupo JM,
Akbari H, Tonn JC, Macdonald D, Vogelbaum M, Chang SM, Davatzikos
C, Villanueva-Meyer JE, Huang RY; Response Assessment in Neuro
Oncology (RANO) group.
Artificial
Intelligence for Response Assessment in Neuro Oncology (AI-RANO),
part 2: recommendations for standardisation, validation, and good
clinical practice.
Lancet
Oncol. 2024 Oct 28;25(11):e589-e601. doi:
10.1016/S1470-2045(24)00315-2. PMID:
39481415. Review: Recommendations˰
ˍ
*Lv W, Wang Y.
Neural Influences on
Tumor Progression Within the Central Nervous System.
CNS
Neurosci Ther. 2024 Oct 29;30(10):e70097. doi:
10.1111/cns.70097. PMID:
39469896. Review. ˍ
Ng AT, Steve T, Jamouss KT, Arham A, Kawtharani S, Assi HI.
The
challenges and clinical landscape of glioblastoma immunotherapy.
CNS
Oncol. 2024 Oct 29;13(1):2415878. doi:
10.1080/20450907.2024.2415878. PMID:
39469854. Review. ˍ
Peker E, Ünal S, Uludağ SB, Zorlu NSY.
Ring-Enhancing
Lesions-Differentiation with MRI.
Br
J Hosp Med (Lond). 2024 Oct 29;85(10):1-20. doi:
10.12968/hmed.2024.0195. PMID:
39475033. Review. ˍ
Zeller SL, Spirollari E, Chandy AM, Hanft SJ, Gandhi CD,
Jhanwar-Uniyal M.
Understanding the
Genomic Landscape of Glioblastoma: Opportunities for Targeted
Therapies.
Anticancer
Res. 2024 Oct 29;44(11):4677-4690. doi:
10.21873/anticanres.17295. PMID:
39477295. Review. ˍ
Zhuo S, Yang S, Chen S, Ding Y, Cheng H, Yang L, Wang K, Yang K.
Unveiling the significance of
cancer-testis antigens and their implications for immunotherapy in
glioma.
Discov
Oncol. 2024 Oct 29;15(1):602. doi:
10.1007/s12672-024-01449-4. PMID:
39472405. Review. ˍ
Alshammari QA, Alshammari SO, Alshammari A, Alfarhan M, Baali FH.
Unraveling the mechanisms of
glioblastoma's resistance: investigating the influence of tumor
suppressor p53 and non-coding RNAs.
Naunyn
Schmiedebergs Arch Pharmacol. 2024 Oct 30. doi:
10.1007/s00210-024-03564-z. PMID:
39476245. Review˰ ˍ
Zhou J, Tan B, Gao F.
Prognostic
values of combined ratios of white blood cells in glioma: a
systematic review and meta-analysis.
Neurosurg
Rev. 2024 Oct 31;47(1):831. doi:
10.1007/s10143-024-03064-x. PMID:
39477886. Review; Meta-analysis˰
ˍ